List of Excipients in Branded Drug IBUPROFEN IB

Generic Drugs Containing IBUPROFEN IB

Company	Ingredient	NDC	Excipient
Family Dollar Services Inc	ibuprofen	55319-393	ANHYDROUS LACTOSE
Family Dollar Services Inc	ibuprofen	55319-393	CARNAUBA WAX
Family Dollar Services Inc	ibuprofen	55319-393	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in IBUPROFEN IB?

# Of NDCs	Excipient
6	ALUMINUM OXIDE
1	ANHYDROUS LACTOSE
1	CARNAUBA WAX

Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Ibuprofen is a mature, low-cost NSAID with limited composition-of-matter protection and intense generic competition. Commercial value is concentrated in formulation performance: faster onset, improved solubility, reduced gastrointestinal exposure, pediatric acceptability, liquid-dose accuracy, topical delivery, and combination products. The strongest opportunities are in differentiated delivery systems rather than conventional immediate-release tablets.

What is the pharmaceutical profile of ibuprofen?

Ibuprofen is a racemic propionic-acid NSAID used for analgesic, antipyretic, and anti-inflammatory indications. It is available in prescription and over-the-counter products in tablets, caplets, softgels, suspensions, chewables, topical gels, creams, and combination products.

Parameter	Commercial relevance
Active ingredient	Ibuprofen, racemic mixture of R- and S-enantiomers
Therapeutically active enantiomer	S-ibuprofen, or dexibuprofen
Typical OTC strengths	200 mg
Common prescription strengths	400 mg, 600 mg, 800 mg
OTC adult daily limit	1,200 mg unless directed by a physician
Typical prescription maximum	Up to 3,200 mg/day under medical supervision
Biopharmaceutics	Low aqueous solubility and high permeability profile
Acid-base behavior	Weak acid, pKa approximately 4.4
Main formulation issue	Dissolution and gastric tolerability
Key safety constraints	Gastrointestinal bleeding, renal toxicity, cardiovascular risk, and hypersensitivity
Regulatory categories	FDA monograph OTC products and approved prescription products

Ibuprofen's low water solubility can delay dissolution, particularly in solid oral products. Particle size reduction, wetting agents, alkalinizing excipients, self-emulsifying systems, amorphous dispersions, and liquid-filled capsules can improve release. Excipients must not undermine dose uniformity, stability, or gastrointestinal safety.

What excipients are used in ibuprofen formulations?

The optimal excipient system depends on the dosage form, target onset, strength, patient population, and manufacturing process.

Immediate-release tablets and caplets

Conventional ibuprofen tablets commonly use a combination of diluents, binders, disintegrants, lubricants, glidants, and coating materials.

Excipient function	Candidate materials	Formulation purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Adds bulk and controls compactability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerates tablet breakup
Wetting agent	Sodium lauryl sulfate, poloxamers, polysorbates	Improves contact between ibuprofen and dissolution media
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Protects the tablet and improves appearance
Taste masking	Sweeteners, flavors, polymer coatings	Supports pediatric and chewable products

Ibuprofen can create process problems because its hydrophobic surface limits wetting and can produce slow or variable dissolution. Excessive magnesium stearate can worsen hydrophobicity. Lubrication time and concentration require tight control.

A practical immediate-release strategy is a high-shear wet granulation or dry granulation process using microcrystalline cellulose or starch, povidone as a binder, crospovidone as a rapid disintegrant, and a low level of lubricant. Sodium lauryl sulfate can improve wetting, but its concentration should be controlled because it may affect tolerability and tablet mechanical properties.

Softgels and liquid-filled capsules

Softgels are a major commercial route for premium ibuprofen products because they can provide rapid dispersion and a differentiated consumer experience.

Useful excipients include:

• Polyethylene glycol 400 or polyethylene glycol 600
• Propylene glycol
• Polysorbates
• Macrogol-based solvents
• Medium-chain triglycerides
• Purified water, where compatible
• Gelatin or non-gelatin capsule shell systems
• Sorbitol or glycerol as shell plasticizers

A liquid-filled system can improve apparent dissolution by presenting ibuprofen in a solubilized, suspended, or partially dissolved state. The formulation must control precipitation after capsule rupture. If ibuprofen crystallizes rapidly in gastrointestinal fluid, the commercial benefit may be smaller than the in-vitro solubilization data suggest.

Softgel development also requires control of shell migration, fill-shell compatibility, oxygen exposure, cross-linking, leakage, and long-term dissolution. Gelatin shell systems remain commercially familiar, while vegetarian shells based on modified starch, carrageenan, or hydroxypropyl starch can support non-animal positioning.

Oral suspensions and pediatric liquids

Pediatric ibuprofen products are highly dependent on excipient selection and dosing-device performance.

Common excipient categories include:

• Suspending agents such as xanthan gum, microcrystalline cellulose with carboxymethylcellulose, and sodium alginate
• Wetting agents such as polysorbates
• Buffers and pH adjusters
• Sweeteners including sucrose, sorbitol, sucralose, and saccharin
• Flavors
• Preservatives where permitted and justified
• Antifoaming agents
• Chelators such as disodium EDTA in selected systems

The product should remain redispersible after storage, resist caking, deliver a uniform dose after shaking, and maintain acceptable viscosity across temperature conditions. High viscosity can improve suspension stability but can reduce pourability and increase dosing error.

The principal commercial opportunity is not a new active ingredient. It is a more acceptable and accurate product for children, caregivers, and older adults. Innovations may include low-sugar formulations, alcohol-free systems, allergen-conscious excipient profiles, improved flavor masking, and dosing syringes calibrated to body weight.

Chewable tablets and orally disintegrating products

Chewable ibuprofen requires taste masking because the active has an unpleasant flavor and acidic character. Suitable approaches include polymer coating, lipid coating, ion-exchange technology, complexation, and matrix embedding.

Excipients may include:

• Mannitol and sorbitol for mouthfeel
• Crospovidone for rapid breakup
• Povidone or maltodextrin as binders
• Sucralose, aspartame, or acesulfame potassium
• Flavors and cooling agents
• Coating polymers such as ethylcellulose or methacrylate copolymers

Sugar-free products can target pediatric and dental-health segments, although polyol load must be managed because excessive sorbitol or mannitol may cause gastrointestinal discomfort.

Topical ibuprofen products

Topical ibuprofen gels and creams use excipients that support skin penetration, spreadability, evaporation, and local tolerability.

Candidate excipients include:

• Ethanol or isopropyl alcohol
• Propylene glycol
• Carbomers
• Hydroxyethylcellulose
• Diethylene glycol monoethyl ether
• Transcutol-type solvents
• Isopropyl myristate
• Phospholipids
• Neutralizing agents such as tromethamine or sodium hydroxide

Topical delivery has the potential to reduce systemic exposure, but permeability across intact skin is limited. The formulation must balance solubilization with thermodynamic activity. A system that holds ibuprofen too tightly in solution may reduce skin flux.

Commercial differentiation can focus on non-greasy texture, rapid drying, lower odor, preservative reduction, improved local deposition, and packaging that limits contamination. Claims relating to reduced systemic risk require clinical substantiation and cannot be inferred solely from excipient selection.

What formulation technologies improve ibuprofen dissolution?

Ibuprofen's weak-acid chemistry creates several formulation options.

Alkaline and salt-based systems

Alkalinization can increase apparent solubility by converting ibuprofen into an ionized form. Sodium ibuprofen and other salt approaches may improve dissolution, but they create additional controls for hygroscopicity, pH, chemical stability, and taste.

Effervescent systems can use sodium bicarbonate, citric acid, and related acid-base pairs to promote rapid dispersion. These products require moisture-protective packaging and careful control of reaction onset.

Particle-size reduction

Micronization increases surface area and can improve dissolution without changing the chemical identity of ibuprofen. The main risks are agglomeration, electrostatic behavior, dust control, content uniformity, and stability of the particle-size distribution.

Nanocrystal approaches can produce larger dissolution gains but require robust stabilization against aggregation. Stabilizers may include polymers, surfactants, or combinations of both.

Amorphous solid dispersions

Polymers such as povidone, copovidone, hydroxypropyl methylcellulose acetate succinate, and Soluplus-type materials can stabilize supersaturated ibuprofen in an amorphous state. The opportunity is stronger dissolution performance at lower doses or faster onset.

The main development barrier is physical stability. Ibuprofen may recrystallize during storage or after contact with gastrointestinal fluid. Differential scanning calorimetry, powder X-ray diffraction, dynamic vapor sorption, and dissolution testing are important development tools.

Lipid and self-emulsifying systems

Lipid-based systems can improve wetting and dispersion. They are suited to softgels, liquid-filled hard capsules, and selected oral suspensions. The critical variables are drug loading, precipitation after dilution, capsule compatibility, and food-effect behavior.

What patents protect ibuprofen formulations?

Ibuprofen's original composition-of-matter protection has expired. The original ibuprofen patent, commonly identified as U.S. Patent No. 3,385,886, issued in 1968 and expired decades ago after accounting for the patent term applicable at that time. Generic ibuprofen therefore has no remaining U.S. compound patent barrier.

Protection category	Status and commercial effect
Ibuprofen compound patent	Expired
Racemic ibuprofen composition	Generally unprotected by enforceable U.S. compound claims
Dexibuprofen or S-ibuprofen	Historic enantiomer and process rights may vary by jurisdiction; core U.S. protection is generally old
Immediate-release tablet	Usually vulnerable to generic substitution
Softgel formulation	May have historical or product-specific formulation patents, but many are expired or narrow
Liquid suspension	Potential protection for taste masking, particle stabilization, or dosing systems
Topical gel	Potential protection for penetration enhancers, concentrations, and vehicles
Manufacturing process	Potentially protectable if novel, non-obvious, and commercially useful
Packaging and dosing device	May support device or combination claims
Method of use	Potentially relevant for specific patient groups, regimens, or combinations

Current Orange Book status must be assessed by product and sponsor because listings change by reference product, dosage form, and patent certification. FDA's Orange Book is the controlling public source for listed patents and exclusivity associated with approved prescription products.[1] OTC monograph products generally do not rely on Orange Book-listed patents in the same manner as approved prescription products. FDA's OTC monograph framework governs permitted active ingredients, concentrations, dosage forms, labeling, and conditions of use.[2]

When does ibuprofen lose exclusivity?

Ibuprofen has already lost its primary U.S. exclusivity. Commercial entry is therefore governed mainly by manufacturing cost, regulatory compliance, retail access, brand recognition, formulation differentiation, and channel economics.

Paragraph IV challenges are relevant only when a generic applicant targets an approved prescription ibuprofen product with an unexpired Orange Book-listed patent. For ordinary generic ibuprofen tablets, capsules, and suspensions, the principal barriers are abbreviated new drug application requirements, bioequivalence, product quality, facility compliance, and commercial scale rather than compound-patent risk.

The absence of a compound patent does not eliminate all litigation risk. A sponsor may assert formulation, dosing, manufacturing, device, or method-of-use patents. Those patents must be tested claim by claim for scope, expiration, validity, and infringement.

What FDA regulatory status applies to ibuprofen products?

FDA permits ibuprofen as an OTC analgesic and antipyretic under the OTC monograph framework when the product satisfies the applicable conditions. The FDA labeling framework includes dosing limits, age restrictions, warnings for gastrointestinal bleeding and cardiovascular events, and contraindication or warning language relevant to hypersensitivity and pregnancy.[2,3]

Prescription ibuprofen products require an approved application or an ANDA referencing a suitable reference product. Generic tablets and capsules generally rely on comparative bioequivalence, while suspensions and other complex dosage forms may require more extensive comparative characterization.

Excipient strategy must comply with:

• FDA inactive-ingredient precedents and route-specific use levels
• United States Pharmacopeia and National Formulary standards
• Microbial limits and preservative effectiveness requirements
• Residual-solvent and elemental-impurity controls
• Nitrosamine and impurity-risk assessments where applicable
• Pediatric safety expectations for colorants, sweeteners, and preservatives

An excipient is not commercially protective merely because it is present in a product. Protection is stronger when the formulation produces a measurable, clinically relevant and reproducible result.

What commercial opportunities exist for ibuprofen excipients?

Premium rapid-onset oral products

Rapid-onset products can use solubilized liquid fills, micronized active, alkaline systems, or lipid dispersion. Retail pricing can exceed standard tablets if the product communicates a clear benefit such as faster relief, easier swallowing, or reduced tablet burden.

The key evidence is comparative dissolution and clinical onset, not simply a higher excipient cost.

Pediatric and caregiver-focused products

Pediatric suspensions remain attractive for products that improve taste, dose accuracy, redispersibility, and sugar management. A dosing syringe and child-resistant packaging can create more value than a marginal change in tablet excipients.

Topical and localized delivery

Topical gels, sprays, patches, and roll-ons can support premium positioning. Penetration-enhancing excipients, skin-feel modifiers, and package design are the main areas for differentiation.

Combination products

Ibuprofen can be combined with acetaminophen, pseudoephedrine, antihistamines, or other actives, subject to applicable regulatory requirements and safety limits. Combination products can command higher retail prices and reduce direct comparison with single-ingredient generics. They also create additional stability, compatibility, labeling, and clinical-risk requirements.

Contract development and manufacturing

Excipient suppliers can capture value by offering complete formulation platforms rather than single ingredients. High-value services include:

• Solubility screening
• Excipient compatibility testing
• Amorphous-dispersion development
• Taste-masking systems
• Ready-to-compress granules
• Liquid-filled capsule formulations
• Pediatric suspension platforms
• Stability-indicating analytical packages
• Scale-up and technology transfer

How strong is the patent estate for ibuprofen?

The core ibuprofen patent estate is weak because the active ingredient is long generic. The strongest remaining opportunities are narrow, product-specific claims covering delivery systems or manufacturing methods.

Asset type	Patent strength	Likely commercial value
New ibuprofen molecule	Very low	Minimal
Conventional 200 mg tablet	Low	Low
Micronized ibuprofen	Low to moderate	Moderate if process is controlled
Salt or buffered formulation	Moderate	Moderate
Amorphous dispersion	Moderate	Potentially high if stable and clinically differentiated
Softgel liquid fill	Moderate	Moderate to high
Pediatric taste-masked suspension	Moderate	Moderate
Topical penetration system	Moderate	Moderate to high
Device-linked dosing system	Moderate	Niche
Novel manufacturing process	Moderate to high if difficult to design around	Depends on cost advantage

Freedom-to-operate analysis should focus on claim scope, prosecution history, patent-family status, terminal disclaimers, continuation applications, and expiration in each target country. Geographic coverage matters because an old U.S. compound patent does not establish freedom to operate in Europe, Japan, China, India, or other jurisdictions.

Which companies compete in ibuprofen formulation products?

Competition includes multinational OTC companies, generic manufacturers, private-label retailers, specialty topical companies, and excipient suppliers. Major commercial brands have historically included Advil, Motrin, Nurofen, and store brands, although ownership, licensing, and market availability differ by country.

The competitive basis is usually:

• Retail distribution
• Brand recognition
• Price
• Dosage-form convenience
• Pediatric acceptance
• Speed-of-relief claims
• Topical user experience
• Combination-product positioning
• Manufacturing reliability

Licensing opportunities are more likely to involve branded OTC rights, regional distribution, formulation technology, or excipient platforms than rights to the ibuprofen molecule itself. Transaction economics depend on territory, dosage form, regulatory status, manufacturing obligations, and brand ownership.

What generic entry risks exist for ibuprofen?

Generic entry risk is high for standard oral products. A conventional 200 mg tablet has low technical differentiation and limited ability to sustain premium pricing.

Risk is lower for products with:

• Difficult-to-reproduce amorphous systems
• Narrow particle-size specifications
• Complex liquid fills
• Taste-masking coatings
• Device-linked dosing
• Specialized topical vehicles
• Proprietary manufacturing controls
• Strong brand and retail placement

The most exposed revenue segments are standard tablets and capsules sold through price-sensitive channels. More defensible segments include pediatric liquids, premium softgels, topical systems, and products with validated onset or tolerability advantages.

Key Takeaways

• Ibuprofen is a mature generic active with expired core composition protection.
• Excipient value is concentrated in dissolution, wetting, taste masking, suspension stability, topical penetration, and patient usability.
• Standard immediate-release tablets have weak patent and pricing protection.
• Softgels, pediatric liquids, amorphous dispersions, buffered systems, and topical products offer stronger commercial differentiation.
• FDA OTC monograph compliance is central for nonprescription products.
• Orange Book and Paragraph IV risks are product-specific and mainly relevant to approved prescription products with unexpired listings.
• The most durable IP opportunities involve formulation, manufacturing, device, and method-of-use claims.
• Generic entry risk is highest for conventional tablets and lowest for technically complex, well-branded delivery systems.
• Excipient suppliers can capture value through integrated formulation platforms, not only commodity ingredient sales.

FAQs

Can ibuprofen be reformulated with common pharmaceutical excipients?

Yes. Microcrystalline cellulose, povidone, crospovidone, sodium starch glycolate, surfactants, polyethylene glycol, carbomers, and suspending agents are commonly relevant, subject to dosage form, route, concentration, and regulatory precedent.

Is ibuprofen suitable for an amorphous solid dispersion?

Yes, but physical stability is the principal risk. Polymer selection, drug loading, humidity control, and recrystallization testing determine whether the technology creates a durable commercial advantage.

Does sodium ibuprofen have stronger commercial potential than free ibuprofen?

It can provide faster dissolution and easier aqueous dispersion, but the advantage depends on stability, taste, hygroscopicity, dose equivalence, and regulatory positioning.

Are ibuprofen topical products protected from generic competition?

Some topical products may have formulation or process patents, but topical ibuprofen remains exposed to competition where claims are expired, narrow, or easy to design around.

What is the most attractive excipient-led ibuprofen opportunity?

A validated formulation platform that combines improved dissolution or onset with patient usability, such as a stable liquid-filled capsule, taste-masked pediatric suspension, or high-performing topical gel, generally has greater value than a conventional tablet excipient substitution.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (2024). 21 CFR Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343
3. U.S. Food and Drug Administration. (2020). Ibuprofen drug label information. DailyMed. https://dailymed.nlm.nih.gov/
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
5. Adams, S. S., Bresloff, P., & Mason, C. G. (1966). Pharmacological differences between the optical antipodes of ibuprofen: Evidence for metabolic inversion of the (-)-isomer. Journal of Pharmacy and Pharmacology, 18(3), 146-154.
6. United States Patent and Trademark Office. (1968). U.S. Patent No. 3,385,886, Substituted phenylalkanoic acids.